Efficacy and safety of Lutai Danshen Baishao granules for treating female melasma: A randomized, double-blind, placebo-controlled trial
Objective: To investigate the potential efficacy and safety of Lutai Danshen Baishao granules (LDBG) for treating female melasma associated with kidney deficiency and blood stasis patterns. Methods: A randomized, double-blind, placebo-controlled trial was conducted at the Third Central Hospital of T...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Journal of Traditional Chinese Medical Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2095754824001078 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586801759387648 |
|---|---|
| author | Meiyu Lyu Yi Yang Jinlian Liu Wenting Fei Min Fu Yunting Hong Hongguo Rong Chun Wang Linyuan Wang Jianjun Zhang |
| author_facet | Meiyu Lyu Yi Yang Jinlian Liu Wenting Fei Min Fu Yunting Hong Hongguo Rong Chun Wang Linyuan Wang Jianjun Zhang |
| author_sort | Meiyu Lyu |
| collection | DOAJ |
| description | Objective: To investigate the potential efficacy and safety of Lutai Danshen Baishao granules (LDBG) for treating female melasma associated with kidney deficiency and blood stasis patterns. Methods: A randomized, double-blind, placebo-controlled trial was conducted at the Third Central Hospital of Tianjin, China from March to December 2023. A total of 110 female patients with melasma linked to kidney deficiency and blood stasis were enrolled and treated with either LDBG or a placebo twice daily for 60 days. Efficacy was assessed through measures such as the total melasma area, reduced melasma area, reduction rate of melasma area, melasma color score, Melasma Area and Severity Index (MASI) score, and traditional Chinese medicine (TCM) symptom score scale. Safety assessments included routine blood and biochemical tests. Results: Participants in both groups were aged 52–63 years, with no significant differences. After the 2-month intervention, the total melasma area decreased in both groups; however, a greater reduction was observed in the test group [462.50 mm2 (12.81%) vs. 100.00 mm2 (3.11%), P < .001]. Moreover, LDBG treatment significantly reduced the MASI and melasma color scores in the test group (P < .05). The total TCM symptom evaluation score significantly decreased (test group: 6.00 vs. placebo group: 7.00, P = .001), with significant relief in symptoms such as improvement in dark lips, nails, and waist soreness in the test group, compared with that in the placebo group (P < .05). Within-group comparisons revealed that TCM syndrome was significantly alleviated in the test group (P < .05). Conclusion: LDBG intervention shows promising effectiveness in reducing female melasma and alleviating TCM syndromes. |
| format | Article |
| id | doaj-art-8aada027d8f6437c8e56a27fe3fff3e2 |
| institution | Kabale University |
| issn | 2095-7548 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Traditional Chinese Medical Sciences |
| spelling | doaj-art-8aada027d8f6437c8e56a27fe3fff3e22025-01-25T04:11:14ZengElsevierJournal of Traditional Chinese Medical Sciences2095-75482025-01-011217178Efficacy and safety of Lutai Danshen Baishao granules for treating female melasma: A randomized, double-blind, placebo-controlled trialMeiyu Lyu0Yi Yang1Jinlian Liu2Wenting Fei3Min Fu4Yunting Hong5Hongguo Rong6Chun Wang7Linyuan Wang8Jianjun Zhang9School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, ChinaTechnology Research and Development Center, Kang'ao (Tianjin) Health Management Centre, Tianjin 300011, ChinaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, ChinaDepartment of Bioengineering, Beijing Polytechnic, Beijing 100176, ChinaThe Centre for Translational Biology, Research Institute of McGill University Health Centre, Montréal H4A 3J1, CanadaDepartment of Public Health, The Third Central Hospital of Tianjin, Tianjin 300170, ChinaCenter for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, ChinaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, ChinaSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, ChinaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China; Corresponding author.Objective: To investigate the potential efficacy and safety of Lutai Danshen Baishao granules (LDBG) for treating female melasma associated with kidney deficiency and blood stasis patterns. Methods: A randomized, double-blind, placebo-controlled trial was conducted at the Third Central Hospital of Tianjin, China from March to December 2023. A total of 110 female patients with melasma linked to kidney deficiency and blood stasis were enrolled and treated with either LDBG or a placebo twice daily for 60 days. Efficacy was assessed through measures such as the total melasma area, reduced melasma area, reduction rate of melasma area, melasma color score, Melasma Area and Severity Index (MASI) score, and traditional Chinese medicine (TCM) symptom score scale. Safety assessments included routine blood and biochemical tests. Results: Participants in both groups were aged 52–63 years, with no significant differences. After the 2-month intervention, the total melasma area decreased in both groups; however, a greater reduction was observed in the test group [462.50 mm2 (12.81%) vs. 100.00 mm2 (3.11%), P < .001]. Moreover, LDBG treatment significantly reduced the MASI and melasma color scores in the test group (P < .05). The total TCM symptom evaluation score significantly decreased (test group: 6.00 vs. placebo group: 7.00, P = .001), with significant relief in symptoms such as improvement in dark lips, nails, and waist soreness in the test group, compared with that in the placebo group (P < .05). Within-group comparisons revealed that TCM syndrome was significantly alleviated in the test group (P < .05). Conclusion: LDBG intervention shows promising effectiveness in reducing female melasma and alleviating TCM syndromes.http://www.sciencedirect.com/science/article/pii/S2095754824001078Female melasmaLutai danshen baishao granulesClinical trialEfficacySafetyTraditional Chinese medicine |
| spellingShingle | Meiyu Lyu Yi Yang Jinlian Liu Wenting Fei Min Fu Yunting Hong Hongguo Rong Chun Wang Linyuan Wang Jianjun Zhang Efficacy and safety of Lutai Danshen Baishao granules for treating female melasma: A randomized, double-blind, placebo-controlled trial Journal of Traditional Chinese Medical Sciences Female melasma Lutai danshen baishao granules Clinical trial Efficacy Safety Traditional Chinese medicine |
| title | Efficacy and safety of Lutai Danshen Baishao granules for treating female melasma: A randomized, double-blind, placebo-controlled trial |
| title_full | Efficacy and safety of Lutai Danshen Baishao granules for treating female melasma: A randomized, double-blind, placebo-controlled trial |
| title_fullStr | Efficacy and safety of Lutai Danshen Baishao granules for treating female melasma: A randomized, double-blind, placebo-controlled trial |
| title_full_unstemmed | Efficacy and safety of Lutai Danshen Baishao granules for treating female melasma: A randomized, double-blind, placebo-controlled trial |
| title_short | Efficacy and safety of Lutai Danshen Baishao granules for treating female melasma: A randomized, double-blind, placebo-controlled trial |
| title_sort | efficacy and safety of lutai danshen baishao granules for treating female melasma a randomized double blind placebo controlled trial |
| topic | Female melasma Lutai danshen baishao granules Clinical trial Efficacy Safety Traditional Chinese medicine |
| url | http://www.sciencedirect.com/science/article/pii/S2095754824001078 |
| work_keys_str_mv | AT meiyulyu efficacyandsafetyoflutaidanshenbaishaogranulesfortreatingfemalemelasmaarandomizeddoubleblindplacebocontrolledtrial AT yiyang efficacyandsafetyoflutaidanshenbaishaogranulesfortreatingfemalemelasmaarandomizeddoubleblindplacebocontrolledtrial AT jinlianliu efficacyandsafetyoflutaidanshenbaishaogranulesfortreatingfemalemelasmaarandomizeddoubleblindplacebocontrolledtrial AT wentingfei efficacyandsafetyoflutaidanshenbaishaogranulesfortreatingfemalemelasmaarandomizeddoubleblindplacebocontrolledtrial AT minfu efficacyandsafetyoflutaidanshenbaishaogranulesfortreatingfemalemelasmaarandomizeddoubleblindplacebocontrolledtrial AT yuntinghong efficacyandsafetyoflutaidanshenbaishaogranulesfortreatingfemalemelasmaarandomizeddoubleblindplacebocontrolledtrial AT hongguorong efficacyandsafetyoflutaidanshenbaishaogranulesfortreatingfemalemelasmaarandomizeddoubleblindplacebocontrolledtrial AT chunwang efficacyandsafetyoflutaidanshenbaishaogranulesfortreatingfemalemelasmaarandomizeddoubleblindplacebocontrolledtrial AT linyuanwang efficacyandsafetyoflutaidanshenbaishaogranulesfortreatingfemalemelasmaarandomizeddoubleblindplacebocontrolledtrial AT jianjunzhang efficacyandsafetyoflutaidanshenbaishaogranulesfortreatingfemalemelasmaarandomizeddoubleblindplacebocontrolledtrial |